DK2768522T3 - The use of sulfated glycosaminoglycan for improving the bioavailability of blood coagulation factors. - Google Patents

The use of sulfated glycosaminoglycan for improving the bioavailability of blood coagulation factors. Download PDF

Info

Publication number
DK2768522T3
DK2768522T3 DK12777895.9T DK12777895T DK2768522T3 DK 2768522 T3 DK2768522 T3 DK 2768522T3 DK 12777895 T DK12777895 T DK 12777895T DK 2768522 T3 DK2768522 T3 DK 2768522T3
Authority
DK
Denmark
Prior art keywords
leu
ser
lys
thr
glu
Prior art date
Application number
DK12777895.9T
Other languages
Danish (da)
English (en)
Inventor
Hubert Metzner
Sabine Zollner
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Application granted granted Critical
Publication of DK2768522T3 publication Critical patent/DK2768522T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK12777895.9T 2011-10-18 2012-10-18 The use of sulfated glycosaminoglycan for improving the bioavailability of blood coagulation factors. DK2768522T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548606P 2011-10-18 2011-10-18
EP11185648 2011-10-18
PCT/EP2012/070615 WO2013057167A1 (en) 2011-10-18 2012-10-18 Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii

Publications (1)

Publication Number Publication Date
DK2768522T3 true DK2768522T3 (en) 2016-11-14

Family

ID=48140372

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12777895.9T DK2768522T3 (en) 2011-10-18 2012-10-18 The use of sulfated glycosaminoglycan for improving the bioavailability of blood coagulation factors.

Country Status (10)

Country Link
US (1) US9393289B2 (enExample)
EP (1) EP2768522B1 (enExample)
JP (1) JP6072810B2 (enExample)
KR (1) KR20140083036A (enExample)
CN (1) CN103889445A (enExample)
AU (1) AU2012318279B2 (enExample)
CA (1) CA2852397A1 (enExample)
DK (1) DK2768522T3 (enExample)
ES (1) ES2600081T3 (enExample)
WO (1) WO2013057167A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511123B2 (en) 2011-10-18 2016-12-06 Csl Behring Gmbh Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIII
AU2015270394B2 (en) 2014-06-06 2017-12-21 Octapharma Ag Preparation comprising Factor VIII and Von Willebrand factor peptides
EP3191524A4 (en) * 2014-09-12 2018-05-30 The Regents of The University of California Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics
CA2975734C (en) 2015-02-06 2025-02-18 Univ North Carolina Chapel Hill OPTIMIZED GENE EXPRESSION CASSETTES FOR HUMAN COAGULATION FACTOR VIII AND THEIR USE
SE539575C2 (en) * 2015-07-30 2017-10-17 Tx Medic Ab Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
CA1341174C (en) 1985-04-12 2001-01-30 John J. Toole Jr. Procoagulant proteins derived from factor viii: c
FR2673632A1 (fr) 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
ATE319817T1 (de) 1996-04-24 2006-03-15 Univ Michigan Gegen inaktivierung resistenter faktor viii
WO2000024759A1 (en) 1998-10-23 2000-05-04 The Trustees Of The University Of Pennsylvania Systemic delivery of gene products via skin
US20040192599A1 (en) 2001-06-15 2004-09-30 Schuh Andre C Gene therapy for hemophilia a
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
SI1624891T2 (sl) 2003-05-06 2013-09-30 Biogen Idec Hemophilia Inc. Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
JP2011503101A (ja) * 2007-11-09 2011-01-27 バクスター・インターナショナル・インコーポレイテッド 修飾された組換え第viii因子およびフォンウィルブランド因子ならびにその使用方法
EP2626079A3 (en) 2008-02-27 2014-03-05 Novo Nordisk A/S Conjungated factor VIII molecules
AU2010284977A1 (en) * 2009-08-20 2012-03-29 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins

Also Published As

Publication number Publication date
KR20140083036A (ko) 2014-07-03
JP2014530246A (ja) 2014-11-17
US20140315815A1 (en) 2014-10-23
AU2012318279B2 (en) 2015-06-04
EP2768522A1 (en) 2014-08-27
EP2768522B1 (en) 2016-07-27
CA2852397A1 (en) 2013-04-25
CN103889445A (zh) 2014-06-25
WO2013057167A1 (en) 2013-04-25
US9393289B2 (en) 2016-07-19
JP6072810B2 (ja) 2017-02-01
AU2012318279A1 (en) 2013-05-02
ES2600081T3 (es) 2017-02-07

Similar Documents

Publication Publication Date Title
CN103917554B (zh) 用于改善重构后纯化的因子viii的稳定性的方法
US9107902B2 (en) Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
KR20150144803A (ko) 복합체
DK2768521T3 (en) Combined use of a sulfated glykosamin glycan and a Hyaluronidase to improve bio-availability of factor VIII
DK2768522T3 (en) The use of sulfated glycosaminoglycan for improving the bioavailability of blood coagulation factors.
HK1197648B (en) Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
HK1197648A (en) Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
KR20210134642A (ko) 재조합 vwf (rvwf)를 이용한 예방 치료 방법
HK1197649B (en) Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii
EP3107561A1 (en) Factor viii b cell epitope variants having reduced immunogenicity